News Focus
News Focus
Replies to #78098 on Biotech Values
icon url

genisi

05/20/09 11:48 AM

#78209 RE: rkrw #78098

Should be more potent than Nexavar and dosed less frequently, but could also be more toxic. Btw, ONXX said at the Deutsche Bank Annual Health Care conference that the structure of F-sorafenib was claimed in its original patent.